How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Maribavir for treating refractory or resistant cytomegalovirus infection after transplant

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about maribavir

Anticipated marketing authorisation indication

2.1 Maribavir (Livtencity) is anticipated to be indicated for treating 'cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT)'.

Dosage in the marketing authorisation

2.2 The dosage schedule will be available in the summary of product characteristics for maribavir.

Price

2.3 The proposed list price for maribavir is commercial in confidence. The company has a commercial arrangement, which would have applied if the technology had been recommended.